Mark Baum: Yeah. That’s a great question, Brooks. And I think my answer is, I really need you, well, first of all, I really need to close the transactions. That’s one thing to engage and negotiating them and papering them up, but it’s another thing to getting them closed. So, once again, I don’t want to get over our skis. I wouldn’t have mentioned it if I didn’t think that we would get at least one of these deals over the line and there are several. But let me get one of them done, any one of them. And I think the answer will be evident that these are highly strategic transactions. These are not simply purchases of products. These are not, in some way, similar to the purchase of the Novartis — the first Novartis deal that we did as an example.
These are highly strategic deals and there are reasons why we want to engage in these transactions. But let me not get too far afield, let’s just get them completed and then we will have this conversation. I think that when our stockholders see one of these deals announced, they will be quite pleased. But let’s get one done.
Brooks O’Neil: Yeah. Thanks for taking my calls — my questions and I am pretty excited the outlook for 2023. Thanks.
Mark Baum: Thank you, Brooks. Thank you so much, Brooks.
Andrew Boll: Thanks, Brooks.
Operator: The next question comes from Sahil Kazmi with B. Riley Securities. Please go ahead.
Sahil Kazmi: Hey. Good afternoon, Mark, Andrew. Congrats on a really — truly transformative 2022 and looking forward to similar progress in 2023 and appreciate you taking our questions. So a couple from us here. Maybe we can start with, just at a high level, as you have reaffirmed your revenue guidance of $135 million to $143 million. Can you talk about how you expect that to be different across the first half and the second half of the year as the NDAs get transferred, the IHEEZO launch comes through?
Mark Baum: Yeah. So the — in terms of the guidance, candidly, I think, when Andrew built his model, we really have not put a whole lot into 2023 on a relative basis for IHEEZO. What we really, I think, modeled out essentially is some growth in our ImprimisRx business, as well as revenues from the first Novartis transaction and the closing of the second Novartis transaction. And I don’t believe we really included that much TRIESENCE in there either and so we have a very modest amount from IHEEZO. What we didn’t want to do, because this is a launch, this is a new product and we can’t guarantee that there will be massive instantaneous uptake of this product. We do think we are going to be very successful in due course. But we would expect the first half to be certainly more biased towards our legacy products and revenues from the Fab Five transaction.
And I think as we get into the second half of the year, as the launch of IHEEZO really takes a footing, that’s when I would expect to see potentially us hopefully getting to where we want to be and possibly even beyond.
Sahil Kazmi: Great. That’s really helpful. And then maybe staying on IHEEZO with some of the reimbursement hurdles sort of getting through with the J-Code and pass-through status. Can you talk about how you are thinking about the pricing strategy there or when you may plan to disclose that to the street?
Mark Baum: Sure. So the price is actually publicly available through Red Book, if you have certain subscriptions, but the price per unit is public and it is $544 per unit.
